Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Steiner

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The American Journal of Cardiology|March 31, 2004
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitusJacques Genest, Jiri Frohlich, George Steiner
European Journal of Biochemistry|December 11, 2002
Structural and compositional changes in very low density lipoprotein triacylglycerols during basal lipolysisJyrki J Agren, Amir Ravandi, Arnis Kuksis, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 9, 2005
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)Jean-Claude Ansquer, Christelle Foucher, Stephanie Rattier, et al.
Diabetes Care|March 5, 2002
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetesJuha Vakkilainen, George Steiner, Jean-Claude Ansquer, et al.
Arthritis and Rheumatism|November 13, 2003
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor StudyIan N Bruce, Murray B Urowitz, Dafna D Gladman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivityJeffrey S Cohn, Bruce W Patterson, Kris D Uffelman, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 29, 2007
In vivo regulation of phenylalanine hydroxylation to tyrosine, studied using enrichment in apoB-100Mahroukh Rafii, Jane M McKenzie, Susan A Roberts, et al.
Atherosclerosis|February 9, 2016
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trialFumiyoshi Tsunoda, Ivor B Asztalos, Katalin V Horvath, et al.
Atherosclerosis|October 19, 2004
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemiaJeffrey S Cohn, Michel Tremblay, Rami Batal, et al.
Circulation|April 1, 2003
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)Juha Vakkilainen, George Steiner, Jean-Claude Ansquer, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The American Journal of Cardiology|March 31, 2004
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitusJacques Genest, Jiri Frohlich, George Steiner
European Journal of Biochemistry|December 11, 2002
Structural and compositional changes in very low density lipoprotein triacylglycerols during basal lipolysisJyrki J Agren, Amir Ravandi, Arnis Kuksis, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 9, 2005
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)Jean-Claude Ansquer, Christelle Foucher, Stephanie Rattier, et al.
Diabetes Care|March 5, 2002
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetesJuha Vakkilainen, George Steiner, Jean-Claude Ansquer, et al.
Arthritis and Rheumatism|November 13, 2003
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor StudyIan N Bruce, Murray B Urowitz, Dafna D Gladman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivityJeffrey S Cohn, Bruce W Patterson, Kris D Uffelman, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 29, 2007
In vivo regulation of phenylalanine hydroxylation to tyrosine, studied using enrichment in apoB-100Mahroukh Rafii, Jane M McKenzie, Susan A Roberts, et al.
Atherosclerosis|February 9, 2016
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trialFumiyoshi Tsunoda, Ivor B Asztalos, Katalin V Horvath, et al.
Atherosclerosis|October 19, 2004
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemiaJeffrey S Cohn, Michel Tremblay, Rami Batal, et al.
Circulation|April 1, 2003
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)Juha Vakkilainen, George Steiner, Jean-Claude Ansquer, et al.
Pageof 3